What a REMS Is, and Why These Labels Do Not Carry One

Answer first: a REMS is a program, not a warning

A risk evaluation and mitigation strategy is something FDA requires a company to run. It is not text on a label. At its heaviest it can decide which prescribers may write for a drug, which pharmacies may dispense it, and whether a patient is enrolled in a registry.

The trigger is a determination by FDA that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks. That phrase repeats through the statute and is the whole standard.

Six approved labels in this category were read in full as structured product data: the two semaglutide injections, the semaglutide tablet label, the two tirzepatide injections, and the orforglipron tablet. The words "REMS" and "Risk Evaluation and Mitigation" appear zero times across all six.

That count is only worth something if the search could have found the phrase, so a control was run in the same pass. A marketed isotretinoin label returned "REMS" 47 times and "iPLEDGE" 34 times. All six of the labels above returned a boxed warning and dozens of mentions of thyroid in the same pass, so the documents were read rather than empty.

What the census does and does not establish

It establishes that the phrase is absent from the text of those six approved labels, measured with an instrument shown to fire on another drug's label in the same run.

It is not a query of FDA's REMS database, and nothing here should be read as one. A separate agency system holds the authoritative list of approved strategies.

It says nothing about any product outside those six. Other products in and near this class exist, and each would need its own reading.

And it is a statement about today's labeling. The statute expressly allows FDA to require a strategy after approval, so absence now is not a permanent condition.

The six factors behind the decision

The statute does not leave the determination to instinct. It lists what the Secretary shall consider in deciding whether a strategy is necessary at initial approval.

The estimated size of the population likely to use the drug. The seriousness of the disease or condition being treated. The expected benefit of the drug for that condition. The expected or actual duration of treatment.

Then the two that carry the most weight in practice. The seriousness of any known or potential adverse events that may be related to the drug, and the background incidence of those events in the population likely to use it. And whether the drug is a new molecular entity.

That fifth factor is the one people skip, and it explains a lot of otherwise puzzling decisions. A serious event that already occurs at some rate in the population being treated is weighed against that background rate, not in isolation.

There is also a procedural guardrail worth knowing. Determinations under this subsection may not be delegated downward. They must be made by individuals at or above the level of those empowered to approve a drug, such as division directors within the Center for Drug Evaluation and Research.

The lightest version of a strategy is a schedule

A common misconception is that any REMS means restricted access. The statute's minimum is far smaller than that.

The minimal strategy is a timetable for submitting assessments of the strategy. It must include an assessment 18 months after the strategy is initially approved, another at three years, and another in the seventh year.

Beyond those three, the frequency is set in the strategy itself and can be increased or reduced as needed.

And it can end. Assessments may be eliminated after the three-year period if the Secretary determines that serious risks of the drug have been adequately identified and assessed and are being adequately managed.

So a drug can carry a strategy that a patient would never notice, consisting entirely of a reporting schedule between the company and the agency.

The middle tier: guides, letters and packaging

Above the timetable sit optional elements FDA may require, each on its own determination.

A Medication Guide, provided for under the same part of federal regulation that governs Medication Guides generally, and a patient package insert if the Secretary determines it may help mitigate a serious risk.

This is where a real distinction lives. A Medication Guide can be required through the Medication Guide regulation on its own, and it can also be required as an element of a strategy. The presence of a guide therefore does not tell you a strategy exists.

A communication plan to health care providers is another optional element. The statute lists what it may include. Letters to providers. Information about the strategy's elements, to encourage implementation or to explain safety protocols such as periodic laboratory tests. Information through professional societies about serious risks and safe-use protocols. And information about drug formulations or properties, and how those may relate to serious adverse events.

Packaging and disposal is a third. Where there is a serious risk of the kind the statute defines, FDA may require unit dose packaging, packaging that provides a set duration, or another packaging system. It may instead require dispensing with a safe disposal packaging or system, where that may mitigate the risk and is sufficiently available.

The heavy tier, and the bar it has to clear

Elements to assure safe use are the restrictive ones, and the statute sets a high threshold before they can be imposed.

They are available where the drug has been shown to be effective but is associated with a serious adverse drug experience. A second condition applies too. The drug can be approved only if, or would be withdrawn unless, those elements are required to mitigate a specific serious risk listed in the labeling.

Read that standard carefully. It is not "this drug has risks". It is "this drug cannot stay on the market without these controls".

Where the bar is met, the elements may require several things. That prescribers have particular training or experience, or are specially certified. That pharmacies, practitioners or health care settings dispensing the drug are specially certified. That the drug be dispensed only in certain settings such as hospitals. That it be dispensed with evidence or documentation of safe-use conditions such as laboratory test results. That each patient be subject to certain monitoring. Or that each patient be enrolled in a registry.

Access protections are written in alongside. Training or certification opportunities must be available to any willing provider from a frontier area through a widely available method, including an online course or by mail, at reasonable cost to the provider.

The burden test

The statute treats restricted access as a cost, not a free good, and builds in a review of that cost.

FDA must seek input from patients, physicians, pharmacists and other providers, through its Drug Safety and Risk Management Advisory Committee or another advisory committee. The question is how these elements may be standardized so as not to be unduly burdensome on patient access, and to minimize delivery-system burden as far as practicable.

It must periodically evaluate whether the elements for one or more drugs actually assure safe use, are not unduly burdensome on patient access, and minimize delivery-system burden.

And it must act on what it learns, by issuing or modifying guidance and by modifying elements for one or more drugs as appropriate.

That is the trade the whole section is built around. Every control that keeps a drug on the market also keeps some patients off it, and Congress required the agency to keep measuring which way that balance is running.

What would change if one were ever required here

The postapproval route is live. Where FDA approved an application without requiring a strategy, it may later require one for that drug. The trigger is that it becomes aware of new safety information and determines a strategy is necessary. That power extends to acting on a supplemental application for a new indication.

The company then has 120 days from notification to submit a proposed strategy, or such other reasonable time as the Secretary requires to protect the public health.

For a reader buying through a telehealth program, the elements that would bite are specific. Prescriber certification would mean the clinician writing for you has to hold it. Pharmacy or setting certification would mean the dispensing pharmacy has to hold it. Documentation of safe-use conditions would mean a lab result has to reach the pharmacy before it fills. Registry enrollment would mean your participation is recorded in a program.

None of those is in place for these six labels today. That is worth knowing in both directions: it is one fewer barrier, and it is also one fewer external check on who is receiving the drug.

Where a compounded preparation sits

The section is written around approved applications throughout. The strategy is submitted as part of an application, the postapproval power runs against the holder of an approved covered application, and the elements attach to labeling approved by FDA.

A compounded preparation has no approved application, so nothing in this section produces a strategy for one. That is a scope fact about the statute rather than a safety finding about any pharmacy.

It does mean the entire tier of controls described above — prescriber certification, pharmacy certification, documented safe-use conditions, patient registries — has no federal source for a compounded preparation. Whatever equivalent exists is the compounder's or the program's own, adopted voluntarily.

The reasonable question to ask a program is therefore not whether it complies with a strategy. It is what it does instead, and who outside the company checks it.